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The intriguing report in this issue of the Journal by Ellis and 
his colleagues (1) from the University of Michigan raises 
several important issues for practicing cardiologists and 
clinical researchers. These investigators described their in- 
stitutional experience with primary angioplasty for acute 
myocardial infarction. The ability of angioplasty as a pri- 
mary technique to establish infarct artery patency, even in 
patients >6 h from symptom onset, is well documented. The 
report further establishes that the traditional risk factors of 
age, left ventricular function and extent of coronary disease 
are important predictors of outcome when this therapeutic 
approach is used. The most interesting questions raised by 
this study, however, concern generic therapeutic decisions 
that must be made on a daily basis by practitioners. When is 
it too late to attempt to achieve reperfusion? When should 
angioplasty be used in preference to thrombolytic therapy 
when reperfusion is desired? How can a single institutional 
report without a control group be used to assist therapeutic 
decision making? 
Timing of reperfusion. Until recently, most experts on 
reperfusion believed that infarct artery reperfusion was 
beneficial only if achieved within 3 to 4 h from the onset of 
occlusion. This belief was based on animal models in which 
measurable myocardial salvage did not occur beyond several 
hours after occlusion. Most of the initial human studies 
seemed to confirm this concept. In trials of intracoronary 
streptokinase (2,3) no improvement in left ventricular ejec- 
tion fraction was found. The Gruppo Italian0 per lo Studio 
della Streptochinasi nell’Infarto Miocardico (GISSI) trial (4) 
found no evidence for improved survival when patients were 
treated with intravenous streptokinase compared with con- 
servative therapy between 6 and 12 h from the onset of 
symptoms. 
In contrast, a meta-analysis of multiple trials of intrave- 
*Editorials published in Journa/ of fhe American College of Cardiology 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the Division of Cardiology, Department of Medicine, Duke Univer- 
sity Medical Center, Durham, North Carolina. 
Address for renrints: Robert M. Califf, MD, Division of Cardiology. 
Department of Medicine, Duke University Medical Center, Box 31123. 
Durham, North Carolina 27710. 
nous thrombolytic therapy in the 1960s and 1970s by Yusuf 
et al. (5) found a significantly improved survival rate in 
patients receiving such therapy beyond 6 h from symptom 
onset compared with the rate in patients receiving placebo in 
this period. This finding led the International Study of Infarct 
Survival (ISIS) group to include patients in their study well 
beyond the time frame of entry in most American trials. In 
the well publicized ISIS-2 results (6), a substantial reduction 
in mortality was observed in patients treated between 6 and 
24 h from symptom onset. This markedly positive finding in 
such a large group of patients has raised a significant 
practical concern about whether all patients coming to 
medical attention within 24 h of the onset of symptoms 
should be treated. 
Careful analysis of left ventricular function after reperfu- 
sion in several trials has further challenged the construct that 
the only reason for improvement in outcome after reperfu- 
sion is “salvage” of myocardium in the traditional sense. 
Reduto et al. (7) were the first to report a poor correlation 
between time to reperfusion and the amount of improvement 
in left ventricular function. We (8) and others (9) subse- 
quently found a weak relation at best between improvement 
in global left ventricular ejection fraction and time to treat- 
ment in a large number of patients with serial left ventricu- 
lograms. Some patients treated very late after symptom 
onset have a large improvement in ejection fraction whereas 
others treated within the first several hours have little or no 
improvement. Overall, the improvement in ejection fraction 
is modest. 
If salvage of myocardium cannot explain all of the benejit 
of thrombolytic therapy, especially in patients treated after 
the usual time for reperfusion, what other explanations can 
we invoke? Much current interest is focused on the concept 
of myocardial healing. In experimental and human models, 
even when reperfusion occurs after the time of expected 
myocardial salvage, less expansion of the infarct zone oc- 
curs during the healing phase (10). Improved healing may 
lead to a lower risk of aneurysm formation and a smaller 
end-systolic volume (11,12). In addition, reperfusion, even 
when late, may help to create a more stable electrophysio- 
logic environment. Several studies (13) have now shown a 
lower rate of abnormal late depolarizations (late potentials) 
on the signal-averaged electrocardiogram (ECG) in patients 
with reperfusion. Two small studies (14,15) have also iden- 
tified a patent infarct-related artery as protective against 
inducible ventricular fibrillation or sustained ventricular 
tachycardia on electrophysiologic testing. 
Although better healing and more stable electrophysio- 
logic properties are the most popular explanations for the 
late benefits of reperfusion therapy, other explanations must 
also be considered. Perhaps many of these patients actually 
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had unstable angina or a critical lesion with intermittent 
patency. Perhaps the patients who benefit have well estab- 
lished collateral vessels to the infarct area and thus have 
myocardial viability for a longer period of time. Establish- 
ment of patency of the infarct-related artery may be helpful 
at a later time when other arteries become unstable or 
occluded. Additionally, the relation between symptom onset 
and onset of coronary occlusion may not be as firm as 
previously believed. Unfortunately, no data currently exist 
to refute or confirm these hypotheses. 
Use of primary angioplasty. The concept of primary an- 
gioplasty to obtain perfusion of the infarct-related vessel is 
attractive in theory, especially to the invasive cardiologist. 
Ellis and colleagues (1) nicely document that patency of the 
infarct artery can be achieved in 90% of patients and, 
through angiographic confirmation, it can be determined 
whether a successful result has been obtained. Furthermore, 
although the authors did not address this issue, patients 
treated with primary angioplasty presumably were not sub- 
ject to the risk of bleeding complications commonly seen 
with thrombolytic therapy. 
A sequential strategy of thrombolytic therapy followed by 
immediate angioplasty in the early hours of acute infarction 
has been addressed by three clinical trials (16-18), all with 
the same results. Immediate angioplasty did not improve the 
clinical outcome, and higher rates of complications were 
observed in patients treated with immediate angioplasty than 
in patients treated with thrombolytic therapy alone. Thus, 
unless the technique of angioplasty can be substantially 
improved by technologic advances in its ability to maintain 
vessel patency without complications, the standard therapy 
for early myocardial infarction should remain rapid admin- 
istration of thrombolytic therapy, with angioplasty reserved 
for patients with recurrent myocardial ischemia or pump 
failure. 
Three possible roles for immediate angioplasty remain, 
however. Patients in whom thrombolytic therapy fails to 
achieve and sustain reperfusion have a worse outcome than 
do patients with successful reperfusion (19). Perhaps the 
plight of these patients could be improved through the use of 
“salvage” or “rescue” angioplasty. A major problem with 
this strategy is that patients who have unsuccessful throm- 
bolytic therapy currently can be identified only with cardiac 
catheterization. A second role of angioplasty may exist when 
a patient can be moved to an expert interventional labora- 
tory within minutes of presentation with acute infarction 
(20). Perhaps in this setting, primary angioplasty is a reason- 
able competitor with thrombolytic therapy. Such a strategy 
could avoid the hemmorhagic risks of thrombolytic therapy. 
This strategy is particularly attractive in the setting of “late” 
reperfusion, where the time to reperfusion may be less 
important. Finally. direct angioplasty may be the only way 
to establish reperfusion in patients with a major contraindi- 
cation to thrombolytic therapy. 
New information needed. Although the report of Ellis and 
colleagues (1) adds significant information, it cannot provide 
answers to the questions. Observational studies without a 
concurrent control group cannot provide data on the relative 
benefits of different therapeutic choices. To their credit, the 
authors have avoided the common mistake of attempting to 
use patients in whom angioplasty was unsuccessful as a 
control group. Patients with unsuccessful angioplasty are 
different from patients in whom the procedure succeeds. 
Furthermore, the very process of failure may actually harm 
these patients, so that their outcome is worse than that of 
untreated control patients. Therefore, rather than causing us 
to embrace or condemn the practice of angioplasty in “late” 
patients, the observations of Ellis et al. should challenge us 
to pursue the important questions that have been raised. 
Several randomized trials of late intervention are cur- 
rently underway or planned. These trials will include several 
that use detailed characterization of ventricular function, 
volume measurements and electrophysiologic status in pa- 
tients treated late versus a control group (21). Large scale 
“megatrials” are also needed, however, to determine 
whether the ISIS-2 results with regard to mortality reduction 
can be confirmed. Investigation of the use of angioplasty to 
open occluded vessels after unsuccessful thrombolysis is 
needed. Several current trials will provide important infor- 
mation on this topic. A trial of great interest would compare 
direct angioplasty with the “conservative” route, which 
yielded such favorable clinical results in the Thrombolysis in 
Myocardial Infarction (TIMI) trial. Although this trial would 
be applicable to clinical practice only in centers with an 
active angioplasty program, many such centers currently 
exist in the United States. As the pieces of the acute 
myocardial infarction puzzle are put into place by these 
trials, clinicians will need to keep an open mind so that new 
concepts and practices can be incorporated into the clinical 
world at an appropriate pace. 
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